Background {#s1}
==========

Individuals with multiple sclerosis (MS) can experience high levels of disability and impaired quality of life for prolonged periods. The costs of the disease in the UK, including health and social care and productivity losses, are high and correlate with disease severity.[@R1] [@R2] It is important to have accurate and up to date information on the prevalence of MS in the UK in order to understand the impact of this disease and to ensure that adequate resources are provided nationally and regionally for people affected by MS. National studies have been carried out in the past, but recent data are lacking.[@R3; @R4; @R5; @R6] To address this need, work on compiling an online national MS register began in 2011 (<http://www.ukmsregister.org>). A dedicated Scottish National MS Register for incident MS cases was established in 2010.[@R7]

The General Practice Research Database (GPRD) is a longitudinal database containing details of patients' demographics, medical diagnoses, referrals to consultants and hospitals, and primary care prescriptions from a representative sample of general practices in the UK.[@R8] Two previous studies have used the GPRD to study the epidemiology of MS in the UK, the first reporting for the period 1993--2000.[@R6] A more recent study investigated the prevalence of MS between 2000 and 2008 stratified by age, sex, geographical region and calendar year.[@R7]

Methods {#s2}
=======

Study design {#s2a}
------------

This was a population-based study using the GPRD. The study protocol was reviewed and approved by the Independent Scientific Advisory Committee (ISAC) of GPRD. No further ethical approval is required for studies using GPRD that do not involve patient contact.

Hypothesis {#s2b}
----------

This was a descriptive study. Its aim was to estimate the incidence and prevalence of MS by age in men and women and to describe secular trends and geographic variations within the UK between 1990 and 2010.

Study population {#s2c}
----------------

The study population included all patients with acceptable data who contributed follow-up time to the database after 1990. GPRD defines a patient\'s data as unacceptable if there is evidence of poor data recording, non-contiguous follow-up or if their registration with the practice is temporary. Eligible follow-up time for each patient started with their practice\'s 'up-to-standard' (UTS) date or the patient\'s date of registration with the practice if this was later. GPRD applies standard criteria to define the date at which any individual practice\'s data become 'UTS' to ensure quality of data.

The first 2 years of follow-up time for each patient were treated as a screening period, and incidence and prevalence rates were calculated for follow-up time after the screening period. We chose this screening period because preliminary analyses showed that incidence rates were high in the first 2 years of follow-up and prevalence rates were low, particularly in the first year. This is probably due to inclusion of patients with prevalent disease whose initial diagnosis pre-dated the computerisation of their practice\'s records.

The follow-up period ended with the earlier of either their transfer-out date or their practice\'s last data collection date.

Outcomes {#s2d}
--------

For GPRD, Read codes for confirmed diagnoses of MS (ie, codes beginning F20) were used. For Hospital Episode Statistics (HES) the International Classification of Diseases (ICD10) code for MS (G35) was used. Incident cases were defined as the first occurrence of a code for MS if it occurred after the 2-year screening period.

Statistical analysis {#s2e}
--------------------

The analysis plan is shown in [figure 1](#JNNP2013305450F1){ref-type="fig"}.

![Analysis plan. GPRD, General Practice Research Database; HES, Hospital Episode Statistics; ONS, Office of National Statistics; MS, multiple sclerosis.](jnnp-2013-305450f01){#JNNP2013305450F1}

GPRD {#s2f}
----

For every patient, the number of days of follow-up available on the GPRD was calculated for each year from 1990 to 2010. We determined whether patients had any prior diagnosis of MS in the GPRD on the 1st January each year and, if not, whether any incident diagnosis occurred during the year.

Incidence rates were estimated from Poisson regression models with log(time at risk) as an offset variable. Prevalence rates were estimated from logistic regression models. The explanatory variables in the models were age, year and region. Geographical regions were defined as Scotland, Wales, Northern Ireland and the 10 Strategic Health Authorities of England. Data for men and women were analysed separately.

Mortality rates were analysed using logistic regression models.

Hospital episode statistics {#s2g}
---------------------------

HES data were available for about 44% of patients in the GPRD from 1997 to 2010. We estimated the prevalence and incidence of MS in these patients over this period of time using GPRD data only, as described above. We compared these rates with those calculated for the same patients using the additional diagnoses obtained from HES. Age-specific rates of under-recording of MS in the GPRD were estimated from inverse polynomials fitted to the ratios of cases identified from HES and the GPRD together versus the GPRD alone. These rates were used to adjust estimates of incidence and prevalence rates for the whole GPRD population.

Office for National Statistics {#s2h}
------------------------------

We applied these adjusted age-specific and gender-specific incidence and prevalence rates to population statistics obtained from the Office for National Statistics (ONS) for the UK population to estimate the absolute numbers of new and prevalent cases of MS in the UK population in 2010.[@R9] We obtained sex-specific and age-specific mortality rates for England and Wales in 2000 and 2010 from the ONS[@R10] and used them to calculate period life expectancy at birth in those years. To estimate the numbers of incident and prevalent cases of MS in the UK population in 2010 for men and women in each decade of life, we calculated incidence and prevalence rates in the entire GPRD population and applied age-specific correction factors to account for under-reporting in GP records alone. We applied the corrected rates in 2010 to the total national UK population based on ONS figures.[@R9]

Results {#s3}
=======

The numbers of patients with UTS follow-up time on the GPRD increased from 1.1 million in 1990 to at least 4.0 million between 2006 and 2010. The GPRD population included about 8% of the UK population in 2010, and their age and sex distributions were similar to those of the whole population ([table 1](#JNNP2013305450TB1){ref-type="table"}).

###### 

Age and sex distributions of the UK population (ONS) and the GPRD population in 2010

             Male         Female                                                        
  ---------- ------------ -------- ----------- ------- ------------ ------- ----------- -------
  Under 20   7 576 800    24.7     583 201     23.7    7 206 500    22.8    560 778     22.3
  20--24     2 213 100    7.2      152 417     6.2     2 096 800    6.6     157 870     6.3
  25--29     2 168 600    7.1      164 375     6.7     2 081 100    6.6     173 444     6.9
  30--34     1 959 800    6.4      167 321     6.8     1 931 700    6.1     167 472     6.7
  35--39     2 084 600    6.8      178 130     7.2     2 117 100    6.7     171 033     6.8
  40--44     2 293 500    7.5      191 992     7.8     2 338 600    7.4     182 945     7.3
  45--49     2 250 100    7.3      190 189     7.7     2 316 100    7.3     181 919     7.2
  50--54     1 964 700    6.4      165 761     6.7     2 016 500    6.4     159 885     6.4
  55--59     1 758 700    5.7      144 410     5.9     1 819 800    5.8     142 460     5.7
  60--64     1 840 100    6.0      149 928     6.1     1 923 500    6.1     151 661     6.0
  65--69     1 412 100    4.6      115 626     4.7     1 519 600    4.8     119 859     4.8
  70--74     1 160 300    3.8      90 976      3.7     1 307 500    4.1     99 859      4.0
  75--79     893 900      2.9      71 287      2.9     1 107 800    3.5     86 266      3.4
  80 plus    1 067 000    3.5      91 963      3.7     1 836 400    5.8     159 309     6.3
  All        30 643 300   100.0    2 457 576   100.0   31 619 000   100.0   2 514 760   100.0

GPRD, General Practice Research Database; ONS, Office for National Statistics.

Secular trends {#s3a}
--------------

The prevalence of MS increased by about 2.4% per year (95% CI 2.3% to 2.6%) in men and women over the study period ([figure 2](#JNNP2013305450F2){ref-type="fig"}A) and reached 285.8 per 100 000 in women (95% CI 278.7 to 293.1) and 113.1 per 100 000 in men (95% CI 108.6 to 117.7) in 2010. The prevalence rates that are below the trend line in the early 1990s may be an artefact due to patients being first diagnosed before their entry to the database, despite the 2-year screening period. There was no change in MS prevalence in patients below the age of 50, but annual rates of increase were over 4% in patients aged ≥60 years ([figure 2](#JNNP2013305450F2){ref-type="fig"}B).

![Secular trends in the prevalence of multiple sclerosis (General Practice Research Database 1990--2010). (A) Prevalence (per 10^5^ (per 100 000) patients) in women and men (all age groups). (B) Variation in prevalence by age group (% change per year, both sexes).](jnnp-2013-305450f02){#JNNP2013305450F2}

There was a consistent downward trend in the incidence of MS in the whole study population over the 20-year study period ([figure 3](#JNNP2013305450F3){ref-type="fig"}A). In 2010, MS incidence in women fell to 11.52 per 100 000/year (95% CI 10.96 to 12.11) and in men to 4.84 per 100 000/year (95% CI 4.54 to 5.16). The rate of decline between 1990 and 2010 was 1.51% per year (95% CI 0.99% to 2.07%) and did not differ between men and women (p=0.682) or with age (p=0.494) ([figure 3](#JNNP2013305450F3){ref-type="fig"}B). This implies that the female-to-male ratio among incident cases, approximately 2.4, did not change significantly over the study period.

![Secular trends in the incidence of multiple sclerosis (General Practice Research Database 1990--2010). (A) Incidence (per 10^5^ patient years) in women and men (all age groups). (B) Variation in incidence by age group (% change per year, both sexes).](jnnp-2013-305450f03){#JNNP2013305450F3}

Mortality rates fell in the GPRD population over the study period. In the 70--79-year age group, for example, they fell from 5.41% per year (95% CI 5.25% to 5.58%) in 1990 to 2.82% per year (95% CI 2.76% to 2.87%) in 2010 in men and from 3.15% per year (95% CI 3.04% to 3.26%) to 1.88% per year (95% CI 1.84% to 1.92%) in women over the same time period. Among other age groups, the proportional decline was similar. The mortality rate among patients with MS was more than twice that of other patients in all age groups and in both sexes, but also declined at a similar proportional rate.

Life expectancy rose from 75.6 to 78.3 years in men and from 79.9 to 81.8 years in women. We applied the age-specific mortality ratios for people with and without MS observed in the present study to estimate changes in life expectancies in people with MS over the same decade. They increased from 61.4 to 65.4 years in men and from 68.7 to 71.6 years in women.

Age trends {#s3b}
----------

The peak incidence of MS occurred at the age of 40 years in women and 45 years in men ([figure 4](#JNNP2013305450F4){ref-type="fig"}A), while peak prevalence rates occurred at the ages of 56 years and 59 years, respectively, ([figure 4](#JNNP2013305450F4){ref-type="fig"}B).

![Incidence and prevalence of multiple sclerosis in women and men by age (General Practice Research Database 1990--2010). (A) Incidence (per 10^5^ patient years). (B) Prevalence (per 10^5^ patients).](jnnp-2013-305450f04){#JNNP2013305450F4}

Regional variation {#s3c}
------------------

There was significant variation in the incidence and the prevalence of MS between regions of the UK (p\<0.001) (see online supplementary Figures 5a and 5b). The highest prevalence and incidence rates were observed in Scotland. Among the other 12 regions of the UK, latitude accounted for 13.8% (men) and 4.0% (women) of the variation in incidence rates, and 2.0% (men) and 0.2% (women) of the variation in prevalence rates, none of which was statistically significant.

Hospital episode statistics {#s3d}
---------------------------

Between 1997 and 2010 GPRD and HES data were available for a subset of patients (approximately 44%, [table 2](#JNNP2013305450TB2){ref-type="table"}). [Tables 3](#JNNP2013305450TB3){ref-type="table"} and [4](#JNNP2013305450TB4){ref-type="table"} show the age-specific and sex-specific prevalence and incidence rates of MS in this subgroup of patients based on the GPRD alone, and the rates when the additional diagnoses recorded in HES are included. HES identified an additional 744 prevalent cases and 121 incident cases in men and 1521 prevalent cases and 227 incident cases in women. GPRD alone underestimated the prevalence of MS by 7.0% in men and 5.5% in women and incidence by 21.3% in men and 17.2% in women over the period 1997--2010. Age-specific correction factors were estimated.

###### 

GPRD study population by year and the subset with HES data available

  Year   GPRD        GPRD with HES
  ------ ----------- ---------------
  1990   1 088 206   
  1991   1 318 334   
  1992   1 508 239   
  1993   1 630 354   
  1994   1 750 630   
  1995   1 862 669   
  1996   2 224 963   
  1997   2 551 363   1 149 379
  1998   2 978 905   1 345 591
  1999   3 561 968   1 592 080
  2000   3 951 452   1 760 716
  2001   4 256 165   1 892 812
  2002   4 508 721   1 949 061
  2003   4 629 896   1 968 050
  2004   4 778 854   2 018 928
  2005   4 858 541   2 059 654
  2006   4 961 506   2 116 992
  2007   5 017 396   2 184 142
  2008   4 989 868   2 223 688
  2009   4 955 179   2 240 931
  2010   4 972 336   1 981 005
  2011   4 665 090   

GPRD, General Practice Research Database; HES, Hospital Episode Statistics.

###### 

Age-specific and gender-specific prevalence of MS using GPRD alone and GPRD with HES (1997--2010)

              Patients (thousands)   GPRD data where HES available   GPRD plus HES            
  ----------- ---------------------- ------------------------------- --------------- -------- -------
  Male                                                                                        
   Under 10   894.6                  5                               0.5             5        0.5
   10--19     1209.3                 33                              2.7             40       3.3
   20--29     1055.6                 230                             21.7            237      22.4
   30--39     1389.2                 1138                            81.9            1166     83.9
   40--49     1514.5                 2255                            148.8           2341     154.5
   50--59     1368.8                 2959                            216.1           3146     229.8
   60--69     1073.6                 2182                            203.2           2337     217.6
   70--79     719.5                  882                             122.5           1054     146.4
  80--89      327.1                  150                             45.8            244      74.5
  90 Plus     48.1                   8                               16.6            16       33.2
   Total      9600.2                 9842                            102.5           10 586   110.2
  Female                                                                                      
   Under 10   855.2                  0                               0.0             8        0.9
   10--19     1096.6                 22                              2.0             34       3.1
   20--29     960.1                  498                             51.8            549      57.1
   30--39     1340.0                 3392                            253.1           3488     260.2
   40--49     1464.2                 6541                            446.7           6724     459.2
   50--59     1341.1                 7845                            584.9           8153     607.9
   60--69     1092.5                 5040                            461.3           5415     495.6
   70--79     856.7                  2014                            235.0           2292     267.5
   80--89     544.6                  563                             103.3           755      138.6
   90 Plus    139.5                  42                              30.1            60       43.0
   Total      9690.6                 25 957                          267.8           27 478   283.5

GPRD, General Practice Research Database; HES, Hospital Episode Statistics; MS, multiple sclerosis.

###### 

Age-specific and gender-specific incidence of MS using GPRD alone and GPRD with HES (1997--2010)

             Patient years (thousands)   GPRD only where HES available   GPRD plus HES          
  ---------- --------------------------- ------------------------------- --------------- ------ -------
  Male                                                                                          
  Under 10   841.0                       0                               0.00            1      0.11
  10--19     1146.2                      6                               0.52            7      0.61
  20--29     974.8                       40                              4.10            42     4.30
  30--39     1294.1                      100                             7.72            107    8.26
  40--49     1429.6                      129                             9.02            143    10.00
  50--59     1301.4                      97                              7.45            123    9.45
  60--69     1013.5                      53                              5.22            75     7.39
  70--79     675.6                       16                              2.36            50     7.40
  80--89     296.2                       4                               1.35            14     4.72
  90 Plus    40.1                        0                               0               4      9.98
  Total      9012.6                      445                             4.93            566    6.28
  Female                                                                                        
  Under 10   804.1                       0                               .00             0      0.00
  10--19     1035.0                      7                               .67             10     0.96
  20--29     870.3                       111                             12.75           121    13.90
  30--39     1250.0                      282                             22.55           300    23.99
  40--49     1387.4                      333                             24.00           358    25.80
  50--59     1277.1                      223                             17.46           270    21.14
  60--69     1035.5                      104                             10.04           142    13.71
  70--79     810.7                       25                              3.08            78     9.62
  80--89     499.2                       7                               1.40            35     7.01
  90 Plus    117.9                       1                               0.84            6      5.08
  Total      9087.3                      1093                            12.02           1320   14.52

GPRD, General Practice Research Database; HES, Hospital Episode Statistics; MS, multiple sclerosis.

Overall estimates of the UK MS population in 2010 {#s3e}
-------------------------------------------------

[Table 5](#JNNP2013305450TB5){ref-type="table"} shows overall estimates of the numbers of incident and prevalent cases of MS in the UK population in 2010 for men and women in each decade of life. We estimate that 126 669 people were living with MS in the UK at the beginning of 2010 (203.4 per 100 000 population) and that 6003 new cases were diagnosed during that year (9.64 per 100 000/year). Women accounted for 72% of prevalent and 71% of incident cases. We also estimated the numbers of incident and prevalent cases of MS in the four countries which comprise the UK ([table 5](#JNNP2013305450TB5){ref-type="table"}).

###### 

Estimated numbers of incident and prevalent cases of MS in the UK population in 2010

                         Population (thousands)   Incidence (/10^5^/year)   Incident cases   Prevalence (/10^5^)   Prevalent cases
  ---------------------- ------------------------ ------------------------- ---------------- --------------------- -----------------
  Male                                                                                                             
   Under 10              3738.8                   0.04                      2                0.3                   12
   10--19                3838.0                   0.41                      16               2.4                   92
   20--29                4381.7                   3.85                      169              19.6                  860
   30--39                4044.4                   7.25                      293              88.8                  3593
   40--49                4543.6                   9.34                      425              166.5                 7568
   50--59                3723.4                   10.12                     377              248.6                 9259
   60--69                3252.2                   8.21                      267              287.0                 9336
   70--79                2054.2                   7.20                      148              183.9                 3779
   80--89                933.2                    6.11                      57               72.7                  679
   90 Plus               133.8                    0.00                      0                35.6                  48
   Total                 30 643.3                 5.72                      1754             114.9                 35 225
  Female                                                                                                           
   Under 10              3566.0                   0.09                      3                0.2                   10
   10--19                3640.5                   1.43                      52               3.0                   110
   20--29                4177.9                   11.62                     486              58.4                  2440
   30--39                4048.8                   20.41                     827              274.0                 11 095
   40--49                4654.7                   24.40                     1136             470.2                 21 887
   50--59                3836.3                   22.12                     849              638.7                 24 502
   60--69                3443.1                   14.70                     506              597.0                 20 555
   70--79                2415.3                   10.10                     244              340.8                 8232
   80--89                1494.1                   8.06                      121              156.6                 2341
   90 Plus               342.3                    7.62                      26               79.1                  271
   Total                 31 619.0                 13.44                     4250             289.2                 91 444
  Both sexes, all ages                                                                                             
  UK                     62 262.3                 9.64                      6003             203.4                 126 669
  England                52 233.9                 9.08                      4745             199.9                 104 451
  Wales                  3006.3                   7.92                      238              168.0                 5052
  Scotland               5222.3                   15.29                     798              255.2                 13 328
  Northern Ireland       1799.8                   12.25                     221              213.2                 3838

MS, multiple sclerosis.

Discussion {#s4}
==========

Principal findings of the study {#s4a}
-------------------------------

We estimate that the prevalence of MS in the UK in 2010, including diagnoses obtained from HES, was 289.0 per 100 000 in women and 115.0 per 100 000 in men. The overall prevalence of MS increased by approximately 2.4% per year between 1990 and 2010 in women and men. This increase in prevalence was due to a convergence of absolute mortality rates in patients with and without MS, the result of mortality rates falling by about 3% per year in both groups. There was no change in MS prevalence in patients below the age of 50, but annual rates of increase were over 4% in patients aged ≥60 years. We observed a decline in the rate at which new cases of MS were diagnosed, and the rising prevalence rate can likely be accounted for by trends in mortality rates. There was a consistent downward trend in overall incidence of MS in the whole study population over the 20-year study period, and the rate of decline did not differ between men and women or with age. It is possible that this is due to new diagnostic techniques which reduced the risk of false positive diagnoses over the study period. The maximum incidence of MS occurred at age 40 years (women) to 45 years (men). We were not able to analyse the effects of prior pregnancy on the age of onset of MS in women in this study, although it has previously been reported that pregnancy reduces the risk of onset of MS.[@R11] We found significant regional variation in incidence and prevalence rates in the UK. We found the highest incidence and prevalence rates among the 13 regions of the UK in Scotland, but no trend with latitude among the other 12 regions. This suggests that the difference between Scotland and other regions of the UK is probably not the result of a consistent trend with latitude, but may involve factors not associated with latitude. We were not able to analyse the different regions of Scotland separately using the GPRD.

Strengths and weaknesses of the study {#s4b}
-------------------------------------

A major strength of this study is that it covers a representative sample of GPs spread geographically throughout the UK, and a patient population with age and sex distributions similar to those of the general UK population. The study population of some 4 million patients provides greater statistical precision than earlier regional surveys. Our analyses depend upon the accuracy of diagnosis and recording of MS by GPs: there may have been miscoding of tentative MS diagnoses as definite MS cases, leading to an overestimate in the number of MS cases, or under-recording may have led to an underestimate in the number of cases. In a systematic review of 212 publications using the GPRD, Herrett *et al* reported that the median proportion of cases with a confirmed diagnosis based on additional internal or external validation was 89% across all disease groups and 81% for nervous system diseases[@R12] but there has not yet been a validation of MS diagnoses specifically within GPRD. We addressed some of the limitations of the GPRD records by also using HES, which allowed us to estimate the extent of under-recording of MS in the GPRD.

Relation to other studies {#s4c}
-------------------------

The prevalence rates we found are slightly higher than the rates reported by Thomas *et al* in 2007, also using the GPRD: 281.0 per 100 000 (95% CI 273.0 to 289.0) among women and 108.0 per 100 000 (95% CI 103.0 to 113.0) among men, with the highest prevalence in those aged 55--64 years.[@R13] This study and our study found maximum prevalence for MS in patients around the age of 60.

Alonso and colleagues reported incidence rates of 7.2 (95% CI 6.5 to 7.7) per 100 000 person-years in women and 3.1 (95% CI 2.6 to 3.5) in men in the UK between 1993 and 2000 in their GPRD study, which are somewhat lower than our findings.[@R6] The UK has a relatively high incidence of MS compared to other countries. An overall incidence rate of MS of 3.6 per 100 000 person-years in women and 2.0 in men was reported in a review of studies of the incidence of MS published between 1966 and 2007.[@R14]

The downward trend in incidence that we found is in contrast to studies in Denmark, where the female incidence of MS has almost doubled since the 1970s while male incidence has remained constant.[@R15] These authors found a general, but not ubiquitous, increase in MS incidence in Western Europe and North America.[@R15] However, they point out that many of the studies included only small numbers of cases and random variations may have contributed to the irregular patterns observed. Moreover, separate surveys carried out and analysed at different times may be subject to methodological differences. It is not clear why our study has detected a decreasing incidence while others have suggested increasing incidence. Changes in awareness of MS and the challenges of diagnosing MS may account for changes incidence over time. However, we could identify no specific reason why the methodology or data source we used should have had an impact on our finding of decreasing incidence of MS over the period of the study.

Sex ratio in MS {#s4d}
---------------

In the current study, the mean female-to-male ratio for MS was 2.4 and there was no trend with time over the 20-year study period. In their 2008 review of published studies on the incidence of MS, Alonso and Hernán reported that the female-to-male ratio increased from 1.4 in 1955 to 2.3 in 2000.[@R14] This increase in the sex ratio for MS is not ubiquitous, however, and there are striking geographic variations. For example, a recent analysis of trends in the sex ratio in MS for individuals born between 1930 and 1989 found a marked increase in Northern Europe (not including the UK) (from 2.09 to 3.77), but only a moderate increase in Southern Europe (from 1.46 to 2.31).[@R16] In contrast, a study in Sweden found a mean female-to-male ratio for MS of 2.62, with no clear trend with year of birth for individuals born between 1931 and 1985.[@R17] A recent review reported a significant increase in the MS prevalence female-to-male sex ratio in the UK between 1949 and 2009---a much longer time period than our study.[@R18] It is possible that this historical trend in female-to-male sex ratio for MS has now stabilised. This may be partly accounted for by changing health-related behaviours of men in recent years, perhaps having more contact with medical services than was the case historically. We are not able to identify any particular reason why the study methodology or data source could have confounded our findings regarding sex-ratio.

Regional variations in MS {#s4e}
-------------------------

A recent study using HES data for the period 1999--2005 showed regional variations in hospital admission rates for MS in England.[@R19] This study found significantly higher MS admissions in more northern regions of England even after adjusting for social deprivation and UK birthplace. Early studies on MS suggested a trend with latitude with increasing prevalence in more temperate climates in Northern and Southern hemispheres.[@R3] [@R20; @R21; @R22; @R23; @R24; @R25; @R26] However, the idea that there is a relationship between latitude and MS incidence or prevalence in Western Europe has been dismissed recently by some authors.[@R15] In contrast, Simpson and colleagues reported that there was a statistically significant positive association between MS prevalence and latitude globally, although there were some exceptions to the latitudinal gradient in some parts of Europe.[@R18]

Regional variation in MS epidemiology may be due to genetic or environmental factors and interactions between them. A study in Ireland found that the HLA DRB1\*15 allele associated with MS susceptibility is more common in areas of higher prevalence.[@R25] The exact role of such factors in the epidemiology of MS remains to be ascertained. One recent study found that the distribution of HLA DRB1 accounted for 52% of the variation in MS prevalence by latitude in Europe,[@R27] whereas another study suggested that non-HLA DRB1 factors play an important role in regional MS variations in Europe.[@R18] For example, it has been suggested that lack of vitamin D may increase susceptibility to MS. This is supported by studies on the effect of month of birth on subsequent risk of MS in Northern and Southern hemispheres.[@R28; @R29] Vitamin D also reversibly blocks the progression of experimental autoimmune encephalomyelitis, a mouse model of MS.[@R30] Further evidence comes from a recent genetic study which demonstrated a causative role for the CYP27B1 gene, which encodes the vitamin D-activating 1-α hydroxylase enzyme.[@R31] Such factors may have a role in increasing the incidence of MS in Scotland relative to other parts of the UK. Further studies are needed to investigate the causative factors of MS, particularly the role of Vitamin D, genetic susceptibility factors and infective agents.

Conclusions {#s5}
===========

This study provides a comprehensive picture of the prevalence and incidence of MS throughout the UK over two decades. It shows that more than 6000 people in the UK were newly diagnosed with MS in 2010 and that patients with MS are living longer, leading to a rising population living with the disease. This has important implications for resource provision in the UK.
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